Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Recurrence 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × tafasitamab × Clear all
NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡